title: Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review.
abstract: BACKGROUND
  Cyclin D1 dysregulation is an early and unifying oncogenic event in patients of multiple myeloma (MM). This may be detected up to 30% cases by immunohistochemistry (IHC) and up to 40-50% cases by molecular studies. However, studies on the clinical significance of cyclin D1 dysregulation in MM have been inconclusive. We aimed to study the pattern of cyclin D1 expression in MM by IHC and correlate with selected clinicopathologic features.
  
  
  METHODS
  Formalin fixed, decalcified, bone marrow trephine sections from 14 symptomatic patients of MM (13 newly diagnosed and one relapsed) were subjected to cyclin D1 IHC by using a rabbit monoclonal antibody to cyclin D1 (clone EPR2241).
  
  
  RESULTS
  Cyclin D1 expression (in ≥10% tumor cell nuclei) was observed in 8 of 14 cases (57%). Cyclin D1 positive (+) group had significantly lower hemoglobin level (P = 0.03) than cyclin D1 negative (-) group (n = 6); though both groups showed no statistical significance (P > 0.05) in regard to age, gender, Durie and Salmon stage, lytic bone lesions, light chain phenotype, creatinine, calcium, lactate dehydrogenase, leukocyte and platelet count and bone marrow histology. Ten of 14 (71.5%) showed a favorable response (follow-up; 7 days to 34 months) to thalidomide and/or bortezomib based chemotherapeutic regimen. Four of eight cyclin D1- patients showed complete response, two had a partial response (PR) and two died of the disease; whereas 4/6 cyclin D1 - patients had PR, one refused definitive therapy and one was lost to follow-up (P > 0.05, Fischer's exact test).
  
  
  CONCLUSIONS
  IHC may be a feasible tool for the demonstration of cyclin D1 expression on adequately processed trephine biopsy specimen in MM patients in a resource poor setting. Negative IHC results should be correlated with molecular techniques for prognostication.
authors.affiliation: Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India.
authors.forename: Somanath
authors.initials: S
authors.lastname: Padhi
authors.affiliation: Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India.
authors.forename: Renu G'boy
authors.initials: RG
authors.lastname: Varghese
authors.affiliation: Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India.
authors.forename: Anita
authors.initials: A
authors.lastname: Ramdas
keywords: Bone marrow; cyclin D1; immunohistochemistry; multiple myeloma; prognosis